Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dr. Jack Zhao United States

Pharmaceutical
Website:
www.JNJ.com
Company Size (Fulltime employees)
5000+
Partnering Objectives
Please specify your partnering goal
Therapeutic
Headquartner in China
No
Biotech/Pharma Category
JNJ
Principal 
Functionality
Research and Development

Hong yu Zhao China

Advanced investment bank of China
Website:
http://www.newone.com.cn
Partnering Objectives
Headquartner in China
Yes
CMSCHINA
Director 

Adam Zhao

Anlong Fund Anlong Bio
Founding Partner CEO 

Sun Zhe China

Founded in 2009,Engaged in the R&D，production and sales of peptide related production.
Website:
www.JYMedtech.com
Partnering Objectives
Headquartner in China
Yes
Shenzhen JYMed Technology Co.,Ltd.
BD Director 

Dr Lihua Zheng China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Website:
http://anhearttherapeutics.com/en/home/
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
Dr Lihua Zheng
AnHeart Therapeutics
LinkedIn logo CBO & co-Founder 
Functionality
Management

Linda Zheng China

A French PHARMA & cosmetics company
Website:
www.Pierre-Fabre.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Pierre Fabre Medicament China
Senior Market Access & Health Economics Director 

Jia Zhilong China

a large hospital
Website:
www.301hospital.com.cn
Partnering Objectives
Headquartner in China
Yes
Chinese PLA general hospital
assistant professor 

Dr Zhinan United States

novel IO Ab therapeutics
Website:
www.Dynamicure.com
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Looking for partners
Headquartner in China
Yes
Dynamicure
Xia 

Sandra Zhong China

Partnering Objectives
Suzhou Kintor Pharmaceuticals, Inc.
BD Director 

Zoe Zhong Singapore

TPG旗下医疗健康投资公司 关注肿瘤设备及创新药
Website:
https://www.tehealthcare.com/
Partnering Objectives
Headquartner in China
No
TE Healthcare group
Marketing Director